{
  "trial_id": "NCT01053026",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "HbA1c \u2264 8.0 % and systolic blood pressure \u2265 140 mmHg",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "age 30-70 years\uff0csystolic blood pressure 140-160 mmHg and HbA1c \u2264 8%",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "no history of ACEI or ARB use within 6 months",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "patients with diabetes mellitus and hypertension",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "active cardiovascular diseases",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "severe hepatic",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "renal dysfunction (CRE \u2265 3 mg/dl\uff0cT-Bil \u2265 3 mg/dl)",
      "label": "not_met",
      "evidence": "quote"
    }
  ],
  "notes": "The patient has type 1 diabetes and presents with shortness of breath and fatigue during activities. He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers.",
  "_meta": {
    "topic_id": "65",
    "trial_id": "NCT01053026",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}